A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders. (September 2015)

• Record Type: Journal Article
• Authors: Andrews, Jessica L.; Fernandez-Enright, Francesca
• Is Part Of: Neuroscience and biobehavioral reviews. Volume 56(2015:Sep.)
• Page Start: 97
• Page End: 114
• Publication Date: 2015-09
• Subjects: Lingo-1 signaling -- Gene expression -- Neurological pathologies -- Psychiatric disorders -- Therapeutic strategies; Psychophysiology -- Periodicals; Human behavior -- Periodicals; Animal behavior -- Periodicals; Neurology -- Periodicals; Behavior -- Periodicals; Ethology -- Periodicals; Neurology -- Periodicals; Psychophysiologie -- Périodiques; Comportement humain -- Périodiques; Animaux -- Mœurs et comportement -- Périodiques; Neurologie -- Périodiques; Animal behavior; Human behavior; Neurology; Psychophysiology; Periodicals; Electronic journals; 573.8
• DOI: 10.1016/j.neubiorev.2015.06.009
• Languages: English
• ISSNs: 0149-7634

Abstract

Highlights: Lingo-1 is a potent negative regulator of myelination and neurite outgrowth. Lingo-1 is expressed throughout the developing and adult brain. Lingo-1 signaling regulates neuronal survival, axon regeneration, oligodendrocyte differentiation. Since its discovery, Lingo-1 has been implicated in a wide range of neurological disorders. Lingo-1 is a promising therapeutic target for neuropsychiatric disorders. Abstract: Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1) is a potent negative regulator of neuron and oligodendrocyte survival, neurite extension, axon regeneration, oligodendrocyte differentiation, axonal myelination and functional recovery; all processes highly implicated in numerous brain-related functions. Although playing a major role in developmental brain functions, the potential application of Lingo-1 as a therapeutic target for the treatment of neurological disorders has so far been under-estimated. A number of preclinical studies have shown that various methods of antagonizing Lingo-1 results in neuronal and oligodendroglial survival, axonal growth and remyelination; however to date literature has only detailed applications of Lingo-1 targeted therapeutics with a focus primarily on myelination disorders such as multiple sclerosis and spinal cord injury; omitting important information regarding Lingo-1 signaling co-factors. Here, we provide for the first time a complete and thorough review of the implications of Lingo-1 signaling in a wide range of neurological and psychiatric disorders, and critically examine its potential as a novel therapeutic target for these disorders.